Compare IOVA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IOVA | TSLX |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2008 | 2011 |
| Metric | IOVA | TSLX |
|---|---|---|
| Price | $7.03 | $18.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $9.00 | ★ $21.61 |
| AVG Volume (30 Days) | ★ 17.2M | 495.7K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 10.82% |
| EPS Growth | ★ 14.84 | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | N/A |
| Revenue This Year | $47.74 | N/A |
| Revenue Next Year | $40.31 | $1.20 |
| P/E Ratio | ★ N/A | $122.93 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.76 | $16.04 |
| 52 Week High | $7.25 | $24.79 |
| Indicator | IOVA | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 71.00 | 58.89 |
| Support Level | $3.57 | $18.50 |
| Resistance Level | N/A | $19.75 |
| Average True Range (ATR) | 0.47 | 0.44 |
| MACD | 0.17 | 0.04 |
| Stochastic Oscillator | 89.70 | 72.77 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.